JP7811176B2 - Ｃ１９ ｃ３８二特異性抗体 - Google Patents

Ｃ１９ ｃ３８二特異性抗体

Info

Publication number
JP7811176B2
JP7811176B2 JP2022552176A JP2022552176A JP7811176B2 JP 7811176 B2 JP7811176 B2 JP 7811176B2 JP 2022552176 A JP2022552176 A JP 2022552176A JP 2022552176 A JP2022552176 A JP 2022552176A JP 7811176 B2 JP7811176 B2 JP 7811176B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
heavy chain
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022552176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516195A5 (https=
JP2023516195A (ja
Inventor
プレスタ，レナード
トゥメ，ポール
ロンバーグ，ニルス
デュラマド，オマール
Original Assignee
バイオグラフ ５５，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオグラフ ５５，インク． filed Critical バイオグラフ ５５，インク．
Priority claimed from PCT/US2021/019685 external-priority patent/WO2021173844A1/en
Publication of JP2023516195A publication Critical patent/JP2023516195A/ja
Publication of JP2023516195A5 publication Critical patent/JP2023516195A5/ja
Application granted granted Critical
Publication of JP7811176B2 publication Critical patent/JP7811176B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022552176A 2020-02-26 2021-02-25 Ｃ１９ ｃ３８二特異性抗体 Active JP7811176B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062981990P 2020-02-26 2020-02-26
US62/981,990 2020-02-26
US202062990330P 2020-03-16 2020-03-16
US62/990,330 2020-03-16
US202063094838P 2020-10-21 2020-10-21
US63/094,838 2020-10-21
PCT/US2021/019685 WO2021173844A1 (en) 2020-02-26 2021-02-25 C19 c38 bispecific antibodies

Publications (3)

Publication Number Publication Date
JP2023516195A JP2023516195A (ja) 2023-04-18
JP2023516195A5 JP2023516195A5 (https=) 2024-03-05
JP7811176B2 true JP7811176B2 (ja) 2026-02-04

Family

ID=77463398

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552176A Active JP7811176B2 (ja) 2020-02-26 2021-02-25 Ｃ１９ ｃ３８二特異性抗体

Country Status (9)

Country Link
US (5) US11299551B2 (https=)
EP (1) EP4110818A1 (https=)
JP (1) JP7811176B2 (https=)
KR (1) KR20220159989A (https=)
CN (1) CN115515980A (https=)
AU (1) AU2021226582A1 (https=)
CA (1) CA3173257A1 (https=)
IL (1) IL295896A (https=)
MX (1) MX2022010549A (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220159989A (ko) * 2020-02-26 2022-12-05 바이오그래프 55, 인크. C19 c38 이중특이적 항체
CN115850479B (zh) * 2021-09-16 2025-08-12 盛禾(中国)生物制药有限公司 一种抗cd24抗体或其抗原结合片段及其应用
AU2024239150A1 (en) * 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies
CN120648654A (zh) * 2024-03-13 2025-09-16 深圳太力生物技术有限责任公司 重组细胞的制备方法、重组细胞及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128586A1 (en) 2009-06-24 2012-05-24 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
JP2016533714A (ja) 2013-10-11 2016-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
JP2018504113A (ja) 2015-01-08 2018-02-15 蘇州康寧傑瑞生物科技有限公司 共通軽鎖を有する二重特異性抗体又は抗体混合物
JP2019522459A (ja) 2016-04-13 2019-08-15 サノフイＳａｎｏｆｉ 三重特異性および／または三価結合タンパク質

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007234621B2 (en) * 2001-01-31 2010-08-26 Biogen Idec Inc. Use of immunoregulatory antibodies in the treatment of neoplastic disorders
US8193318B2 (en) * 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
AU2005235811B2 (en) 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CA2611814A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
WO2008037257A2 (en) 2006-09-26 2008-04-03 Genmab A/S Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR101911438B1 (ko) 2012-10-31 2018-10-24 삼성전자주식회사 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법
SG11201509361TA (en) 2013-05-28 2015-12-30 Numab Ag Novel antibodies
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
EP3481410A2 (en) 2016-07-08 2019-05-15 Paul C. Tumeh Compositions and treatment methods for cancer immunotherapy
JP7033328B2 (ja) 2016-08-16 2022-03-10 エピムアブ バイオセラピューティクス インコーポレイテッド 一価の非対称タンデムＦａｂ二重特異性抗体
US20200385478A1 (en) 2018-01-05 2020-12-10 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
WO2019195535A1 (en) 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof
WO2019197979A1 (en) 2018-04-10 2019-10-17 Y-Biologics Inc. Cell engaging binding molecules
WO2020180398A1 (en) 2019-01-14 2020-09-10 The Regents Of The University Of California Compositions and methods for modulating cellular internalization
WO2021146464A1 (en) 2020-01-15 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Pericyte-sparing therapy
WO2021173844A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
KR20220159989A (ko) * 2020-02-26 2022-12-05 바이오그래프 55, 인크. C19 c38 이중특이적 항체
JP2024535705A (ja) * 2021-08-25 2024-10-02 バイオグラフ ５５，インク． 免疫抑制性ｂ細胞を標的化する抗体
IL310941A (en) * 2021-08-25 2024-04-01 Biograph 55 Inc Methods for the treatment of cancer associated with immunosuppressive B cells
AU2024239150A1 (en) * 2023-03-21 2025-10-02 Biograph 55, Inc. Cd19/cd38 multispecific antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128586A1 (en) 2009-06-24 2012-05-24 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
JP2016533714A (ja) 2013-10-11 2016-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性ドメイン交換共通可変軽鎖抗体
JP2018504113A (ja) 2015-01-08 2018-02-15 蘇州康寧傑瑞生物科技有限公司 共通軽鎖を有する二重特異性抗体又は抗体混合物
JP2019522459A (ja) 2016-04-13 2019-08-15 サノフイＳａｎｏｆｉ 三重特異性および／または三価結合タンパク質

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Frontiers in Immunology，2019年，Vol.10:1613，pp.1-12

Also Published As

Publication number Publication date
US20210269545A1 (en) 2021-09-02
US20260103536A1 (en) 2026-04-16
IL295896A (en) 2022-10-01
US20220185907A1 (en) 2022-06-16
CN115515980A (zh) 2022-12-23
KR20220159989A (ko) 2022-12-05
US12540194B2 (en) 2026-02-03
US12509527B2 (en) 2025-12-30
EP4110818A1 (en) 2023-01-04
JP2023516195A (ja) 2023-04-18
US20220185908A1 (en) 2022-06-16
CA3173257A1 (en) 2021-09-02
US20220185906A1 (en) 2022-06-16
US20220363774A2 (en) 2022-11-17
AU2021226582A1 (en) 2022-10-13
MX2022010549A (es) 2022-11-16
US11299551B2 (en) 2022-04-12

Similar Documents

Publication Publication Date Title
JP7811176B2 (ja) Ｃ１９ ｃ３８二特異性抗体
JP7257971B6 (ja) 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
WO2021173844A1 (en) C19 c38 bispecific antibodies
US12173081B2 (en) CD19/CD38 multispecific antibodies
US20240392000A1 (en) Methods of treating cancers associated with immunosuppressive b cells
US20240352156A1 (en) Antibodies targeting immunosuppressive b cells
JP2025535498A (ja) Ｃｄ２４に対する抗体およびその使用
CN120693178A (zh) 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途
EP4069736A1 (en) Antibodies against lif and uses thereof
HK40043135B (zh) 针对人tim-3的单克隆抗体

Legal Events

Date Code Title Description
RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221224

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260123

R150 Certificate of patent or registration of utility model

Ref document number: 7811176

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150